Akkermansia Bacteria: A Key to Gut and Metabolic Health

Akkermansia muciniphila is a beneficial bacterium that lives in the human gut, specifically within the intestinal mucus layer. Discovered in 2004, this anaerobic, gram-negative microbe has drawn significant scientific interest due to its unique ability to degrade mucin, the primary component of the gut’s protective lining. It constitutes 1-5% of the total gut microbiome in healthy adults. This bacterium’s presence is consistently detected in human colonic mucosal samples, with studies suggesting its role in maintaining overall gut health.

Role in Gut Health

Akkermansia muciniphila maintains gut barrier integrity. It degrades mucin, which is a protein that forms the mucus layer lining the intestines. This degradation process is not destructive; instead, it stimulates the production of new mucin, thereby thickening and strengthening the intestinal barrier. A robust mucus layer is important for preventing harmful substances, such as toxins and pathogens, from crossing into the bloodstream, a condition often referred to as “leaky gut.”

The bacterium’s activity also produces short-chain fatty acids (SCFAs), particularly acetate and propionate, from mucin breakdown. These SCFAs serve as energy sources for other beneficial gut bacteria, contributing to a healthy microbial ecosystem. Propionate can be a precursor to butyrate, another beneficial SCFA. This process helps to maintain gut homeostasis and supports the overall health of the intestinal environment.

Influence on Metabolic Health

Akkermansia muciniphila is linked to various metabolic conditions. Higher levels of this bacterium are associated with improved metabolic health markers, including better glucose metabolism and reduced insulin resistance. In the context of obesity and type 2 diabetes, a lower abundance of Akkermansia muciniphila has been observed.

Supplementation with Akkermansia muciniphila in animal studies reduces body weight gain, decreases fasting blood glucose by approximately 21.2%, and improves glucose tolerance by about 22.1%. Its mucin-degrading activity contributes to a stronger gut barrier, which can reduce systemic inflammation often associated with metabolic disorders. The bacterium’s production of propionate can stimulate the secretion of glucagon-like peptide-1 (GLP-1), a hormone that plays a role in regulating glucose metabolism and appetite suppression. This multifaceted influence highlights its potential impact on metabolic health.

Factors Affecting Akkermansia Levels

The abundance of Akkermansia muciniphila in the gut is influenced by several factors, particularly dietary choices. Fiber-rich foods, which act as prebiotics, can indirectly support its growth by feeding other beneficial bacteria. Specific dietary components, such as polyphenols found in cranberries, grapes, and pomegranates, have been shown to increase Akkermansia levels. For instance, cranberry extract and Concord grape polyphenols have increased Akkermansia abundance significantly in some animal studies.

Fermented products can also contribute to a favorable gut environment for Akkermansia. Lifestyle factors like calorie restriction are associated with increased Akkermansia muciniphila abundance, although these studies often involve increased dietary fiber intake as well. Conversely, a high-fat diet has been consistently shown to reduce Akkermansia muciniphila levels in animal models. The antidiabetic drug metformin has also been observed to increase Akkermansia abundance and short-chain fatty acid production.

Akkermansia as a Therapeutic Target

Research on Akkermansia muciniphila as a direct therapeutic agent is progressing. Both live and pasteurized forms are being investigated. Pasteurized Akkermansia has shown promising results in clinical trials, with one study demonstrating improved insulin sensitivity by 28.62% and reduced insulinemia by 34.08% in overweight or obese individuals. It also led to a slight reduction in body weight and fat mass.

The European Food Safety Authority (EFSA) has approved pasteurized Akkermansia muciniphila as a safe novel food, allowing its commercialization as a food supplement. This form is considered a postbiotic, retaining beneficial effects even after heat treatment. While promising, it is important to note that most current research on Akkermansia as a therapeutic agent is based on animal models, and further human clinical investigations are underway to fully understand its impact, safety, and efficacy across various conditions.

A Bacterial Cell Model: The Basic Blueprint of Life

Can You See Gut Bacteria With a Microscope?

Molecular Impact of Alcohols on Bacterial Cells